Cardiff Oncology Inc

CRDF

Company Profile

  • Business description

    Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

  • Contact

    11055 Flintkote Avenue
    San DiegoCA92121
    USA

    T: +1 858 952-7570

    E: [email protected]

    https://www.cardiffoncology.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    33

Stocks News & Analysis

stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks

Moated ASX share crashes amid weak trading update

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,015.4048.700.54%
CAC 407,905.6348.270.61%
DAX 4024,274.9357.560.24%
Dow JONES (US)44,632.99204.57-0.46%
FTSE 1009,112.5023.82-0.26%
HKSE25,176.93347.52-1.36%
NASDAQ21,098.2980.29-0.38%
Nikkei 22540,654.7019.85-0.05%
NZX 50 Index12,855.9780.44-0.62%
S&P 5006,370.8618.91-0.30%
S&P/ASX 2008,756.4051.800.60%
SSE Composite Index3,615.726.010.17%

Market Movers